(Corrects to add dropped words ‘met primary endpoint’ in headline)
Sept 26 (Reuters) - Array Biopharma Inc :
* Global regulatory submissions planned for 2017
* Array Biopharma and Pierre Fabre announce columbus phase 3 study of encorafenib plus binimetinib for BRAF-mutant melanoma met primary endpoint
* Generally well-tolerated and safety profile overall consistent with prior encorafenib plus binimetinib clinical trial results Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.